HMO: why UNH, Cigna, Humana fail our quality screen

2026-06-23 · By Lubin Danilo, founder of Lubin Investment

HMOs (Health Maintenance Organizations) are the dominant health insurers in the United States. Despite their size, UnitedHealth, Humana and Cigna struggle in our quality screener. The reasons are structural: low real FCF margins, regulatory pressure, unpredictable claim cycles, and valuations above our entry targets.

• HMOs are the dominant health insurers in the US, valued at hundreds of billions.
• Despite their size, UNH, Humana and Cigna struggle in our quality screener.
• UNH scores 6/10. Humana 5/10. Cigna 7/10.
• The reasons are structural: low FCF margins, regulation, claim cycles.
• P&C and life insurers pass our screener better than HMOs.

What is an HMO?

An HMO (Health Maintenance Organization) is a type of health insurer in the United States that operates as a managed network. Insured members choose a Primary Care Physician within the network, and the insurer covers care in exchange for a monthly premium. The main players are UnitedHealth Group (UNH), Cigna (CI) and Humana (HUM). These companies manage tens of millions of insured members and are valued at hundreds of billions of dollars. Yet in our quality screener, their scores are disappointing.

UnitedHealth (UNH): 6/10, scandals and margin pressure

UnitedHealth scores 6/10 in our screener. Its free cash flow per share is at a level where our entry target is set at $201.58, against a current price of $406.68, a 50% premium. Failing criteria include declining FCF per share, low cash profitability, margin compression, and high valuation. On the fundamental side, UNH faces structural headwinds: insurance scandals (claim denials, government investigations), growing political pressure on billing and prior authorization practices. These factors weigh on the perceived quality of the model.

Humana (HUM): 5/10, Medicare Advantage pressure

Humana scores 5/10. The company is highly concentrated in Medicare Advantage, the government health insurance program for American seniors. This market is regulated by the Centers for Medicare & Medicaid Services (CMS), which sets reimbursement rates annually. When CMS reduces its rates, Humana's margins collapse. The company has suffered several loss-making quarters due to this mechanism. Our screener identifies this structural fragility: FCF growth is neither regular nor sufficiently solid.

Cigna (CI): 7/10, the best of the three but with flaws

Cigna scores 7/10, making it the best of the three HMOs in our screener. But some criteria remain failing: the conversion of earnings to cash and valuation. Cigna has diversified its model with Express Scripts (drug management) which generates more recurring revenues. But the core health insurance business has the same structural fragilities as its competitors: limited real FCF margins, exposure to CMS regulation, and political uncertainties around the Affordable Care Act.

Why HMOs struggle in our method

The fundamental reason is simple: HMOs have structurally low real FCF margins. They collect premiums but pay their insured members' medical care. Medical payments (Medical Loss Ratio) absorb an average of 80 to 90 cents of every premium dollar. What remains for administration, marketing, and profit is limited. Regulation requires maintaining this ratio within a narrow range. This contrasts sharply with property and casualty (P&C) insurers like Cincinnati Financial (CINF), Kinsale Capital, or Erie Indemnity, or specialty insurers like AIZ or SIGI, which have very different business models and regularly pass our screener with high scores.

FAQ

What exactly is an HMO?

An HMO is an American health insurer that manages a network of doctors and hospitals. Insured members pay a monthly premium and consult within the network. The insurer covers care. The main HMOs are UnitedHealth, Humana, Cigna, Aetna (CVS Health) and Centene.

Why do P&C insurers pass your screener better than HMOs?

P&C (property and casualty) insurers have different business models: they collect premiums on risks (fires, accidents, disasters) and invest the float. Their real FCF margins are structurally higher than HMOs. Companies like CINF, SIGI, Erie Indemnity or Kinsale Capital achieve very high scores in our screener.

Do UNH's scandals affect your analysis?

Our analysis is primarily financial: we evaluate the quality of the numbers, not the scandals. But scandals have a financial effect: they create provisions, legal costs, political pressure that can change regulation. These elements are reflected in the trajectory of margins and FCF, which our screener detects.

Can one invest in HMOs despite these low scores?

Our method does not forbid investing in companies with low scores: it identifies maximum quality companies at reasonable prices. A score of 6/10 or 7/10 can correspond to a decent company, not an elite one. Some investors may be attracted by HMO relative valuations or dividends. This is not our approach, but it is not a universal judgment either.

Are there health insurers that pass your screener?

Yes. Some more specialized insurers or those with different models can pass our screener with better scores. Our database includes specialty P&C insurers (Cincinnati Financial, Erie Indemnity, Kinsale, SIGI, AIZ) that have very different FCF profiles from traditional HMOs.

Analyser une action sur Lubin Investment

About the author

Written by Lubin Danilo, founder of Lubin Investment. A self-taught individual investor, I have analyzed stocks through their fundamentals for several years and invest my own money with this method. I codified it into a tool that judges a company's quality and its price separately, using criteria drawn from the financial literature (Warren Buffett, Michael Mauboussin, Aswath Damodaran).